Publications by authors named "Lin-Bo Cai"
Article Synopsis
- Epithelioid glioblastoma (Ep-GBM) is a rare and aggressive brain tumor variant, with a high recurrence rate and poor prognosis; there’s currently no established standard treatment for it.
- In a study of 58 Ep-GBM cases, common symptoms included headaches and dizziness, and the median survival rates were 12.7 months for progression-free survival and 29.1 months overall; reoperation after recurrence notably improved survival time.
- Key factors influencing survival included tumor spread before initial surgery, the number of adjuvant temozolomide cycles received, and radiotherapy; extending the Stupp regimen with more temozolomide cycles could enhance outcomes for patients.
Increased vascular permeability facilitates metastasis. Cancer-secreted exosomes are emerging mediators of cancer-host crosstalk. Epstein-Barr virus (EBV), identified as the first human tumor-associated virus, plays a crucial role in metastatic tumors, especially in nasopharyngeal carcinoma (NPC).
View Article and Find Full Text PDFArticle Synopsis
- Lymphatic metastasis is a frequent issue in nasopharyngeal carcinoma (NPC), a type of cancer associated with the Epstein-Barr virus (EBV), though the virus's exact role in metastasis was not well understood.
- * The study found that EBV promotes lymph node (LN) metastasis in NPC by enhancing lymphangiogenesis through the secretion of VEGF-C, with specific cellular mechanisms involving PHLPP1 and hyperactivity of AKT/HIF1a.
- * Targeting this EBV/VEGF-C pathway could provide new treatment strategies for NPC patients experiencing lymphatic spread, as evidenced by the analysis of various proteins associated with this process in clinical specimens.*
Leptomeningeal metastasis (LM) is a rare but lethal complication of advanced non-small cell lung cancer (NSCLC) that has a devastating impact on patient survival and quality of life. Osimertinib, an irreversible tyrosine kinase inhibitor, is approved as a therapy for advanced NSCLC with epidermal growth factor receptor (EGFR) mutation. However, the efficacy and optimal dosage of osimertinib in the treatment of NSCLC patients with LM who harbor uncommon EGFR mutations have yet to be fully investigated.
View Article and Find Full Text PDF: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) antibody that has shown preclinical and clinical anticancer activity in cerebral glioblastoma multiforme (GBM). We conducted a phase II, single-arm, multicenter clinical trial to evaluate the benefit of adding nimotuzumab to current standard chemo-radiotherapy for patients with GBM with positive EGFR expression. : Newly diagnosed patients with histologically proven single supratentorial GBM and epidermal growth factor receptor (EGFR) positive expressions were recruited.
View Article and Find Full Text PDFObjective: We retrospectively studied the efficacy of bevacizumab as salvage therapy for recurrent malignant glioma with a focus on the overall survival (OS).
Methods: Patients who received a therapy other than surgery for recurrent malignant glioma were included. Efficacy was evaluated using MRI.
Background: Current evidence suggests that a majority of the inherited risks play a major role in glioma susceptibility, and glioma is due to the co-inheritance of multiple low-risk variants. These variants can be identified through association studies including such as genome-wide association studies (GWAS), which has led the glioma epidemiology researchers to focus on identifying potential disease-causing factors.
Methods: We evaluated and validated 10 tag single nucleotide polymorphisms (tSNPs) in seven genes associated with glioma susceptibility in a Han Chinese population, including 301 glioma cases and 302 controls, using a multiplexed single nucleotide polymorphism (SNP) MassEXTEND assay.